TRAVERE THERAPEUTICS INC. - COMMON STOCK

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

03 Mar 2023 13:05:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

28 Feb 2023 19:36:49 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Proposed Public Offering of Common Stock

27 Feb 2023 13:01:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

23 Feb 2023 13:01:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

17 Feb 2023 13:04:25 By Nasdaq GlobeNewswire

Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results

16 Feb 2023 13:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Feb 2023 14:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

08 Feb 2023 13:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Jan 2023 16:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Provides Corporate Update and 2023 Outlook

09 Jan 2023 04:00:01 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 13:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Dec 2022 14:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

16 Nov 2022 14:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease

15 Nov 2022 05:00:02 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

09 Nov 2022 13:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Third Quarter 2022 Financial Results

27 Oct 2022 13:01:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022

26 Oct 2022 13:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Report Third Quarter 2022 Financial Results

20 Oct 2022 13:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy

13 Oct 2022 13:05:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Oct 2022 14:00:00 By Nasdaq GlobeNewswire